Comparing Research in Sermorelin and Growth Hormone
Studies suggest growth hormone-releasing hormone analogs include the peptide Sermorelin, which may have many uses, including promoting faster tissue repair, increasing bone density, increasing hunger hormone signaling, regulating cell aging, and ensuring that growth hormone (GH) levels remain stable over time.
Research in the supplementation of growth hormone to mitigate growth hormone insufficiency dates back almost a century. The extraction of early GH from pituitary glands was a risky and costly procedure. Genentech was an early adopter of the recombinant growth hormone manufacturing technology, which greatly reduced manufacturing costs and improved overall performance in 1981.
There are two possible outcomes when the usual mechanisms that regulate GH secretion are disrupted. Firstly, there is a much more dramatic increase and decrease in GH levels than is “normal.” This raises the dangers of excessive amounts of GH and may alter the peptide’s effect on organs and tissues. In stark contrast to the typical pattern of GH secretion, this phenomenon is known as square-wave physiology.
Suppressing feedback mechanisms by large quantities of GH is a further concern. This may completely disrupt the above-depicted 24-hour schedule of GH secretion. Although this is less of an issue when managing growth hormone insufficiency, it is still an issue.
Both issues mentioned above are hypothesized to be alleviated when conducting similar studies in Sermorelin. Research suggests that Sermorelin acetate may keep GH secretion patterns constant since it appears to be amenable to typical physiological feedback processes. Investigations purport that Sermorelin is most effectively understood as an GH set-point booster that may keep typical patterns intact.
Findings imply that Sermorelin acetate is better than GH since, as time passes, the organism observed in the study usually develops a resistance to the peptide, rendering it ineffective. When the number of receptors for a particular ligand decreases, tachyphylaxis occurs. In the context of growth hormone (GH), an overdose or prolonged presentation of the peptide reduces the hormone’s efficacy since the organism reduces the number of GH receptors. The only way to lessen this impact is to present substance vacations when the compound is not presented to allow the receptors to recuperate.
According to the research, Sermorelin does not seem to cause tachyphylaxis. Indeed, data suggests that Sermorelin’s presentation may enhance the quantity of GHRH-Rs, an impact that remains mostly enigmatic.
Sermorelin Peptide and Muscle
Researchers speculate that Sermorelin acetate may promote muscle mass rather than fat like other GH secretagogues. Peptides have been hypothesized to promote skeletal and muscular development rather than fat storage. Like other GH supplements, Sermorelin appears to be a possible fat-burning peptide. Because testosterone offers relative advantages, hypogonadism is more often observed in male animal species in the laboratory, exhibiting an absence of sex hormones to a greater extent. Although testosterone is considered still to be the most effective hormone for mitigating hypogonadism, Sermorelin acetate is being investigated for its relevance in this context. Specialists are especially curious about Sermorelin’s potential to halt the process of muscular atrophy.
Sermorelin Peptide and Wounds
It’s unsurprising that peptides like Sermorelin, which appear to raise GH levels, are theorized to have a good influence on the pace of wound healing since GH is a significant activator. However, Sermorelin’s potential to lessen scar development and size may be a greater surprise. Although scars facilitate tissue repair, they also have the potential to disrupt normal tissue and organ function. A researcher’s holy grail would be to find a way to reduce scarring without sacrificing wound healing potential. In the cardiovascular system, this is more evident than anywhere else.
Sermorelin Peptide and Sleep
The impact of sleep in cell aging is well-studied, which should not be surprising considering Sermorelin’s advocates as a possible anti-cell aging peptide. Both the impacts of sleep on cell aging and the effects of age on sleep have been hypothesized to be mitigated by Sermorelin, but restoring a more youthful rhythm of GH secretion might pivotal. Sermorelin has been speculated to have the potential to be among the most effective GHRH-R agonists for combating the consequences of cell aging and managing growth hormone shortage caused by cell aging, as suggested by Dr. Richard Walker of the International Society for Advanced Research in Aging (SARA).
Researchers interested in further studying this peptide may visit biotechpeptides.com for the highest quality research compounds available. Please note that none of the substances mentioned in this article have been approved for human consumption and should, therefore, not be used by unlicensed professionals outside of contained environments such as laboratories. This article serves educational purposes only and does not, by any means, encourage consumption.
References
[i] R. F. Walker, “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?,” Clin. Interv. Aging, vol. 1, no. 4, pp. 307–308, 2006, doi: 10.2147/ciia.2006.1.4.307.
[ii] S. T. Wahid, P. Marbach, B. Stolz, M. Miller, R. A. James, and S. G. Ball, “Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues,” Eur. J. Endocrinol., vol. 146, no. 3, pp. 295–302, Mar. 2002, doi: 10.1530/eje.0.1460295.
[iii] D. K. Sinha et al., “Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males,” Transl. Androl. Urol., vol. 9, no. Suppl 2, pp. S149–S159, Mar. 2020, doi: 10.21037/tau.2019.11.30.
[iv] L. L. Bagno et al., “Growth Hormone–Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy,” J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis., vol. 4, no. 4, Mar. 2015, doi: 10.1161/JAHA.114.001464.
[v] R. M. Kanashiro-Takeuchi et al., “New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor,” Oncotarget, vol. 6, no. 12, pp. 9728–9739, Mar. 2015.
